ʻO Semaglutide a me Tirzepatide nā lāʻau lapaʻau GLP-1 hou i hoʻohana ʻia no ka mālama ʻana i ka maʻi diabetes type 2 a me ka momona.
Ua hōʻike ʻo Semaglutide i nā hopena maikaʻi aʻe i ka hōʻemi ʻana i nā pae HbA1c a me ka hoʻonui ʻana i ke kaumaha. Ua ʻae ʻia ʻo Tirzepatide, kahi moʻolelo pālua GIP/GLP-1 receptor agonist, e ka US FDA a me ka European EMA no ka mālama ʻana i ka maʻi diabetes type 2.
Ka pono
Hiki i ka semaglutide a me ka tirzepatide ke hoʻemi nui i nā pae HbA1c i nā poʻe maʻi me ka maʻi diabetes type 2, no laila e hoʻomaikaʻi ai i ka mana glucose koko.
Ma ke ʻano o ka pohō kaumaha, hōʻike pinepine ʻo tirzepatide i nā hopena maikaʻi aʻe i hoʻohālikelike ʻia me semaglutide.
Pilikia naʻau
Ua hōʻike ʻo Semaglutide i nā pōmaikaʻi cardiovascular i ka hoʻāʻo ʻo SUSTAIN-6, me ka hōʻemi ʻana i nā pilikia o ka make ʻana o ka maʻi cardiovascular, non-fatal myocardial infarction, a me ka make ʻole.
Pono nā hopena cardiovascular o Tirzepatide e noiʻi hou aku, ʻoi aku ka hopena o ka hoʻokolokolo SURPASS-CVOT.
Na Apono Laau Laau
Ua ʻae ʻia ʻo Semaglutide ma ke ʻano he mea hoʻohui i ka meaʻai a me ka hoʻomaʻamaʻa e hoʻomaikaʻi i ke kō koko koko i nā pākeke me ka maʻi maʻi type 2, a e hōʻemi i ka hopena o nā hanana cardiovascular nui i nā pākeke me ka maʻi diabetes type 2 a hoʻokumu ʻia ka maʻi cardiovascular.
Ua ʻae ʻia ʻo Tirzepatide ma ke ʻano he mea hoʻohui i ka meaʻai i hoʻemi ʻia-calorie a hoʻonui i ka hana kino no ka mālama ʻana i ke kaumaha mau i nā pākeke me ka momona a i ʻole ke kaumaha a ma ka liʻiliʻi hoʻokahi comorbidity pili i ke kaumaha.
Hooponopono
Hoʻohana pinepine ʻia ka semaglutide a me ka tirzepatide ma o ka hoʻokele subcutaneous.
Loaʻa iā Semaglutide kahi hoʻomākaukau waha.
Ka manawa hoʻouna: Jul-08-2025